True Blue (TBI) upgraded at Deutsche from Hold to Buy, Deutsche Bank said. $16 price target. Company is leveraged to rising ISM new orders index and could see more demand following Hurricane Sandy.
Vertex Pharmaceuticals (VRTX) downgraded at Goldman from Neutral to Sell, Goldman Sachs said. $43 price target. Have a more cautious outlook for the company's cystic fibrosis portfolio.
Watson Pharmaceuticals (WPI) upgraded at Piper from Neutral to Overweight, Piper Jaffray said. $103 price target. Company offers growth at a reasonable price.
STOCK COMMENTS / EPS CHANGES
LinkedIn (LNKD) numbers boosted at Citi. Shares of LNKD now seen reaching $135, according to Citigroup. Estimates also upped, as the company is gaining market share. Buy rating.
Priceline.com (PCLN) numbers raised at Goldman. Shares of PCLN now seen reaching $770, according to Goldman Sachs. Estimates also increased, as the company is realizing higher bookings growth. Buy rating.
Pfizer (PFE) estimates, target reduced at BMO. PFE estimates were cut through 2013, BMO Capital said. Company is being hurt by the stronger dollar. Outperform rating and new $29 price target. Starbucks (SBUX) estimates, target raised at BofA/Merrill. Shares of SBUX now seen reaching $60, according to Bank of America/Merrill Lynch. Estimates also increased, as new products are driving growth. Buy rating. >To submit a news tip, email: tips@thestreet.com.Follow TheStreet on Twitter and become a fan on Facebook.
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
